Angiokeratomas, Fabry disease and enzyme replacement therapy: Still a challenge [3]

British Journal of Dermatology

Volumn 152, Issue 1, 2005, Pages 177-178

  Mohrenschlager M ^a   Henkel, V ^b   Ring, J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE;

COMORBIDITY; ENZYME REPLACEMENT; FABRY DISEASE; GENE MUTATION; HEMANGIOKERATOMA; HUMAN; LETTER; MEDICAL DECISION MAKING; MENTAL DISEASE; PRIORITY JOURNAL; ACNE; ALOPECIA AREATA; ASPARTYLGLYCOSAMINURIA; ATOPIC DERMATITIS; BETA MANNOSIDOSIS; ENZYME ACTIVITY; FUCOSIDOSIS; GANGLIOSIDOSIS; PSORIASIS; SIALIDOSIS; SUICIDE;

ALPHA-GALACTOSIDASE; ANGIOKERATOMA; DIAGNOSIS, DIFFERENTIAL; FABRY DISEASE; HUMANS; SKIN NEOPLASMS;

EID: 13244298471     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06359.x     Document Type: Letter

References (18)

1. Linthorst GE, De Rie MA, Tjiam KH et al. Misdiagnosis of Fabry disease: importance of biochemical confirmation of clinical or pathological suspicion. Br J Dermatol 2004; 150:575-7.
2. Moḧrenschlager M, Braun-Falco M, Ring J, Abeck D. Fabry disease. Recognition and management of cutaneous manifestations. Am J Clin Dermatol 2003; 4:189-96.
3. Möhrenschlager M, Ring J, Abeck D. Skin manifestations of Fabry disease. JAMA 2001; 286:1315.
4. Epinette WW, Norins AL, Drew AL et al. Angiokeratoma corporis diffusum with α-L-fucosidase deficiency. Arch Dermatol 1973; 107:754-7.
5. Wenger DA, Sattler M, Mueller T et al. Adult GM1 gangliosidosis: clinical and biochemical studies on two patients and comparison to other patients called variant or adult GM1 gangliosidosis. Clin Genet 1980; 17:323-34.
6. Gehler J, Sewell AC, Becker C et al. Clinical and biochemical delineation of aspartyl-glycosaminuria as observed in two members of an Italian family. Helv Pediatr Acta 1981; 36:179-89.
7. Miyatake T, Atsumi T, Obayashi T et al. Adult type neuronal storage disease with neuraminidase deficiency. Ann Neurol 1979; 6:232-44.
8. Kanzaki T, Yokota M, Mizuno N et al. Novel lysosomal glycoaminoacid storage disease with angiokeratoma corporis diffusum. Lancet 1989; i:875-7.
9. Ries M, Whybra C, Wendrich K et al. Diagnosis of Fabry disease in children: quality assurance aspects. J Inherit Metab Dis 2001; 24 (Suppl. 2):132-3.
10. Schindler D, Bishop DF, Wallace S et al. A new neuroaxonal dystrophy due to lysosomal α-N-acetylgalactosaminidase deficiency. N Engl J Med 1989; 320:1735-40.
11. Frustaci A, Chimenti C, Ricci NR et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose infusion therapy. N Engl J Med 2001; 345:25-32.
12. Flynn DM, Lake BD, Boothby CB et al. Gut lesions in Fabry's disease without a rash. Arch Dis Child 1972; 47:26-33.
13. Grewal RP. Psychiatric disorders in patients with Fabry's disease. Int J Psychiatry Med 1993; 23:307-12.
14. Wendrich K, Whybra C, Ries C et al. Neurological manifestation of Fabry disease in male patients. J Inherit Metab Dis 2001; 24 (Suppl. 2):139.
15. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139:846-50.
16. Schiffmann R, Kopp JB, Austin HA et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285:2743-9.
17. Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy of Fabry's disease. N Engl J Med 2001; 345:9-16.
18. Möhrenschlager M, Ring J, Abeck D. Options in the treatment of Fabry disease. Pediatr Dermatol 2003; 20:373-4.